Nutex Health（NUTX）株式概要
Nutex Health Inc.は、米国でヘルスケア・サービスおよび運営会社として事業を展開している。 詳細
NUTX Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
MS
Community Contributor
Nutex (NUTX) is undervalued
I believe earnings are forecast to increase. There is robust demand and robust earnings growth.
View narrativeUS$165.64
FV
28.2% 割安 内在価値ディスカウント19.30%
Revenue growth p.a.
21
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Nutex Health Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$118.91 |
| 52週高値 | US$193.07 |
| 52週安値 | US$77.21 |
| ベータ | 2.07 |
| 1ヶ月の変化 | 9.71% |
| 3ヶ月変化 | 17.64% |
| 1年変化 | -25.66% |
| 3年間の変化 | 62.95% |
| 5年間の変化 | n/a |
| IPOからの変化 | -98.02% |
最新ニュース
ナラティブの更新 • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.ナラティブの更新 • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.ナラティブの更新 • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).
ナラティブの更新 • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).Recent updates
ナラティブの更新 • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.ナラティブの更新 • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.ナラティブの更新 • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).ナラティブの更新 • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).ナラティブの更新 • Mar 11
NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience
Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.ナラティブの更新 • Feb 25
NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience
Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).ナラティブの更新 • Feb 11
NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay
Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.ナラティブの更新 • Jan 27
NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk
Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).ナラティブの更新 • Jan 12
NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds
Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.ナラティブの更新 • Dec 26
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.ナラティブの更新 • Dec 12
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).Seeking Alpha • Sep 10
Nutex: Diagnosed With A Case Of Fair Value
Summary Nutex Health shows strong revenue growth and a healthy balance sheet, but recent issues with SEC filings and a short report caused the stock to decline. Growth prospects hinge on the execution of expansion, especially in the IPA segment, which could drive future cash flow at low cost. Competitive pressures, cyclical capex, and significant stock-based compensation limit upside and warrant a deeper margin of safety for investors. At current levels, NUTX is not undervalued; I recommend a Hold rating and would only consider buying below $65 for better risk-reward. Read the full article on Seeking Alpha新しいナラティブ • May 28
Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges
Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.分析記事 • Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...分析記事 • Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target
The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...分析記事 • Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...Seeking Alpha • Aug 23
Nutex Health GAAP EPS of -$0.03, revenue of $58.05M
Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.株主還元
| NUTX | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | -5.9% | -0.4% | 1.0% |
| 1Y | -25.7% | 16.3% | 28.7% |
業界別リターン: NUTX過去 1 年間で16.3 % の収益を上げたUS Healthcare業界を下回りました。
リターン対市場: NUTXは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。
価格変動
| NUTX volatility | |
|---|---|
| NUTX Average Weekly Movement | 11.9% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: NUTXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: NUTXの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2011 | 1,005 | Tom Vo | www.nutexhealth.com |
Nutex Health Inc.は、米国でヘルスケア・サービスおよびオペレーションを行う企業である。3つのセグメントで事業を展開：病院、人口健康管理（PHM）、不動産。病院事業では、小規模病院、専門病院、外来診療部門のネットワークを開発・運営し、救急外来、入院診療、行動医学などの医療サービスを提供している。また、CTスキャン、X線、MRI、超音波などの画像診断サービス、ラボラトリーサービス、院内薬局なども提供している。PHM事業では、独立医師会（IPA）などのプロバイダーネットワークの構築・運営や、IPA向けのクラウドベースの技術プラットフォームを通じて、関連病院や医師グループに対する経営・管理・その他のサポートサービスを提供している。不動産部門は土地と病院の建物を所有、賃貸している。ヌーテックス・ヘルス・インクは2011年に設立され、テキサス州ヒューストンに本社を置いている。
Nutex Health Inc. 基礎のまとめ
| NUTX 基礎統計学 | |
|---|---|
| 時価総額 | US$818.05m |
| 収益（TTM） | US$96.38m |
| 売上高(TTM) | US$879.95m |
8.5x
PER（株価収益率0.9x
P/SレシオNUTX は割高か？
公正価値と評価分析を参照収益と収入
| NUTX 損益計算書（TTM） | |
|---|---|
| 収益 | US$879.95m |
| 売上原価 | US$434.85m |
| 売上総利益 | US$445.10m |
| その他の費用 | US$348.72m |
| 収益 | US$96.38m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 14.01 |
| グロス・マージン | 50.58% |
| 純利益率 | 10.95% |
| 有利子負債／自己資本比率 | 9.3% |
NUTX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 08:47 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Nutex Health Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| William Sutherland | Benchmark Company |
| Eugene Mannheimer | Freedom Capital Markets |
| Anthony Vendetti | Maxim Group |